Marvel Biosciences has identified two new pediatric-friendly liquid formulations of its lead compound MB-204, designed for children with neurodevelopmental disorders who have difficulty swallowing pills. Supported by a Canadian government grant, these formulations offer high oral bioavailability, long-term stability, and ease of manufacturing, improving drug delivery for conditions like autism and Rett syndrome. This advancement enhances Marvel's clinical readiness and strengthens its intellectual property as it moves toward Phase I trials and regulatory engagement.
The FTSE 100 index fell slightly, dragged down by mining stocks reacting to China's slower GDP growth of 4.3% in Q2, its weakest in three years. Despite this, oil prices remained steady amid US-Iran tensions. PayPal shares jumped over 14% following r...
The Goldman Sachs Future Tech Leaders Equity ETF (GTEK) has delivered a 48.9% return year-to-date, nearly doubling the 25% return of the Vanguard Information Technology ETF (VGT). Unlike VGT, which heavily invests in mega-cap tech giants like Nvidia,...
